Letter to the Editor: Matching-adjusted indirect comparison between garadacimab and lanadelumab for the long-term prophylactic treatment of patients with hereditary angioedema
Journal of Comparative Effectiveness Research · 2026-11 · 15 (11)
DOI: 10.57264/cer-2026-0018 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of Comparative Effectiveness Research, 2026-11. Verfasst von Irmgard Andresen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Takeda Pharmaceuticals International AG, Zurich, Switzerland. Die Arbeit nennt 19 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Takeda Pharmaceuticals International AG, Zurich, Switzerland.
- Takeda Development Center Americas, Inc., Lexington, MA 02421, USA.
- Takeda Pharmaceuticals USA, Inc., Cambridge, MA 02142, USA.
Zitieren
APA
Andresen, I., Khutoryansky, N., Feeny, S. L., & Dangel, A. (2026). Letter to the Editor: Matching-adjusted indirect comparison between garadacimab and lanadelumab for the long-term prophylactic treatment of patients with hereditary angioedema. Journal of Comparative Effectiveness Research, 15(11). https://doi.org/10.57264/cer-2026-0018
Vancouver
Andresen I, Khutoryansky N, Feeny SL, Dangel A. Letter to the Editor: Matching-adjusted indirect comparison between garadacimab and lanadelumab for the long-term prophylactic treatment of patients with hereditary angioedema. Journal of Comparative Effectiveness Research. 2026;15(11). doi:10.57264/cer-2026-0018
BibTeX
@article{Andresen2026,
author = {Andresen, Irmgard and Khutoryansky, Natalie and Feeny, Sarah L and Dangel, Alissa},
title = {Letter to the Editor: Matching-adjusted indirect comparison between garadacimab and lanadelumab for the long-term prophylactic treatment of patients with hereditary angioedema},
journal = {Journal of Comparative Effectiveness Research},
year = {2026},
volume = {15},
number = {11},
doi = {10.57264/cer-2026-0018}
}
EUVIMED